MIRA Pharmaceuticals (MIRA) vs NanoViricides (NNVC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
NanoViricides (NNVC) has outperformed MIRA Pharmaceuticals (MIRA) over the past year, losing 9.1% versus a loss of 44.4%. NanoViricides is the larger company by market cap ($33.2 million vs $31.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MIRA | NNVC |
|---|---|---|
| Share price | $0.7455 | $1.30 |
| Market cap | $31.33M | $33.18M |
| 1-day change | +6.05% | -0.76% |
| YTD return | -50.63% | +15.04% |
| 1-year return | -44.37% | -9.09% |
| 5-year return | — | -73.36% |
| EPS (TTM) | $-1.14 | $-0.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.45 | $2.23 |
| 52-week low | $0.60 | $0.85 |
| Distance from 52-week high | -69.57% | -41.70% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +369.48% | +361.54% |
| Average volume | 585.04K | 443.75K |
| Shares outstanding | 42.02M | 25.52M |
| Employees | — | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NNVC has outperformed MIRA by 35.3 percentage points over the past year.
About MIRA Pharmaceuticals
MIRA stock →MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders.
Health Care · Biotechnology: Pharmaceutical Preparations
About NanoViricides
NNVC stock →NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection; The latter, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
MIRA vs NNVC FAQ
Which is bigger, MIRA Pharmaceuticals or NanoViricides?
NanoViricides (NNVC) is larger, with a market capitalization of $33.18M compared with $31.33M for MIRA Pharmaceuticals (MIRA).
Which stock has performed better over the past year, MIRA or NNVC?
NNVC returned -9.09% over the past 12 months, compared with -44.37% for MIRA (price return, excluding dividends). Past performance does not predict future results.
Are MIRA Pharmaceuticals and NanoViricides in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.